Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

TerminatedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

April 10, 2025

Study Completion Date

April 11, 2025

Conditions
Krabbe Disease
Interventions
BIOLOGICAL

FBX-101

A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (hGALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.

Trial Locations (1)

48109

University of Michigan Hospitals - Michigan Medicine, Ann Arbor

Sponsors
All Listed Sponsors
lead

Forge Biologics, Inc

INDUSTRY